Company intelligence / Profile preview
Techfields Inc.
- Ownership
- Private
- Development stage
- Phase 3
Overview
Techfields is developing a proprietary transdermal drug delivery platform that transforms approved therapeutics into prodrugs with improved tissue penetration, bioavailability, and safety. Their lead asset, Ibuprofenamine Hydrochloride (X0002), is in Phase 3 trials for osteoarthritis knee pain. Additional programs target COVID‑19 complications, depression, obesity, Parkinson’s disease, and more. Early clinical results suggest enhanced efficacy and safety profiles compared to traditional oral or injectable formulations[1][2][5][6].
- Therapeutic areas
- PsychiatryCardiovascularRheumatologyEndocrinologyNeurologyInfectious Diseases
- Modalities
- Small molecule drugsProdrugs (modified approved drugs for improved delivery)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Techfields Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Techfields Inc..